UPDATE: RBC Capital Upgrades Seagen (SGEN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to UPDATE: RBC Capital Upgrades Seagen (SGEN) to Outperform
August 15, 2022 7:53 AM EDT
Guggenheim analyst Michael Schmidt lowered the price target on Seagen (NASDAQ: SGEN) to $194.00 (from $204.00) while maintaining a Buy rating.... More
August 12, 2022 1:39 PM EDT
(Reuters) -U.S. drugmaker Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using its drug technology.
The companies have been locked in a legal battle over patents on Daiichi and AstraZeneca Plc's breast-cancer... More
August 12, 2022 1:14 PM EDT
(Updated - August 12, 2022 1:15 PM EDT)
Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (Daiichi Sankyo) relating to the parties 2008 collaboration agreement for the use of Seagens antibody-drug conjugate (ADC) technology. The... More
